Hong Kong HIV Therapeutics Market Analysis Report [2022-30]

Hong Kong HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Hong Kong HIV therapeutics market will reach a value of $29.48 Mn from $22.05 Mn in 2022, growing at a CAGR of 3.7% during 2022-2030. The market is primarily dominated by local players such as Roche, Sanofi, and HKG Epitherapeutics. The market is driven by government initiatives, the prevalence of HIV infections, and awareness about HIV / AIDS. The HIV therapeutics market in Hong Kong is segmented by type, product, geography, end user, and distribution channel.

ID: IN10HKPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Hong Kong AUTHOR: Dr. Vishwa Modhia

Buy Now

Hong Kong HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Hong Kong HIV therapeutics market will reach a value of $29.48 Mn from $22.05 Mn in 2022, growing at a CAGR of 3.7% during 2022-2030.

Hong Kong is a special administrative region (SAR) of the People's Republic of China. As of 2020, the voluntary and anonymous HIV/AIDS reporting system generated a total of 10,785 reports of HIV infection and 2,230 cases of AIDS for the Department of Health in Hong Kong. Cocktail therapy is a combination of drugs used to prevent the virus from replicating.

In Hong Kong, there are currently about 20 kinds of drugs. The HIV care cascade is a model that describes the phases of HIV care that people living with the virus (PLHIV) go through in order, from initial diagnosis through antiretroviral therapy ("ART") and viral suppression. The total healthcare spending in Hong Kong in 2020 was $22.7 Bn, or 6.2% of the GDP, making it one of the highest in Asia.

Hong Kong HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers

A straightforward resource has been created in Hong Kong for practicing doctors, healthcare professionals, and anyone else interested in HIV treatment. An interactive table of frequently used antiretrovirals called Anti-HIV Med is an example of such a tool. Additionally, the proactive involvement of community organizations has increased the reach and scope of HIV programs, better enabling them to serve the needs of a wider range of populations. Hong Kong's overall HIV response became much more structured and long-lasting in the 1990s with the establishment of the Advisory Council on AIDS (ACA) and the AIDS Trust Fund (ATF).

Market Restraints

Before being sold in Hong Kong, pharmaceuticals and medicines must be registered with the Pharmacy and Poisons Board of the Department of Health. The registration procedure costs between $5,000 and $10,000 and lasts roughly 9 to 15 months.

Competitive Landscape

Key Players

HKG Epitherapeutics (HKG)
Sanofi (HKG)
Roche (HKG)
AstraZeneca
Novartis
GlaxoSmithKline
Johnson & Johnson

Healthcare Regulations and Reimbursement Policies

The Department of Health (DH) is the regulatory body in Hong Kong charged with regulating the authorization and administration of HIV therapeutics. The DH is in charge of ensuring the quality, safety, and efficacy of medications sold on the market. To control the HIV therapeutics market in Hong Kong, the DH collaborates with other regulatory organizations like the Pharmaceuticals and Healthcare Products Regulatory Agency (PHARMA) and the Centre for Health Protection (CHP).

The Hospital Authority (HA) in Hong Kong is the organization that handles government reimbursement for HIV therapeutics. The HA is in charge of overseeing Hong Kong's public healthcare system and offers access to necessary medical services, including HIV treatment. HIV medications are covered by the public healthcare system and are provided to patients at no cost or at a reduced cost. A variety of antiretroviral medications and related services are available to patients with HIV/AIDS who seek treatment at public hospitals and clinics.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.